About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Pancreatic Cancer Clinical Trials in Nashville | 290 Studies

Clinical Trials Pancreatic CancerNashville

Pancreatic Cancer Clinical Trials in Nashville

Find 290 clinical trials for pancreatic cancer near Nashville, Tennessee. Connect with research centers in your area.

All Pancreatic Cancer trials nationwide All trials in Nashville

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 61-80 of 290 trials

Active not recruitingA Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid TumorsThis is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-7909\] plus a mixture of…NCT05726864·Gilbert, Arizona and 27 others Active not recruitingStudy of JANX008 in Subjects With Advanced or Metastatic Solid Tumor MalignanciesThis study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK)…NCT05783622·Duarte, California and 17 others

Pancreatic Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedA Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid TumorsThis study is a first-in-human, Phase 1, open label, multicenter, dose escalation study with expansion at the RP2D, to evaluate the safety, tolerability, and preliminary efficacy…NCT05074472·Phoenix, Arizona and 8 others

RecruitingA Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid TumorsThis is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1)…NCT05941507·Los Angeles, California and 7 others

TerminatedPhase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic CancerTo evaluate the safety and efficacy of ACP-196 and nab paclitaxel/gemcitabine in subjects with previously untreated metastatic pancreatic cancer using standard response criteriaNCT02570711·Ventura, California and 9 others

Active not recruitingColorectal Cancer Screening in Cystic FibrosisThis multi-center study will compare multi-target DNA and quantitative FIT stool-based testing to colonoscopy in individuals with Cystic Fibrosis (CF) undergoing colon cancer…NCT05362344·Los Angeles, California and 25 others

RecruitingStudy of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic CancerThe study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects…NCT05254171·Hot Springs, Arkansas and 92 others

Active not recruitingClaudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic AdenocarcinomaThis is a Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally…NCT05539430·Tampa, Florida and 8 others

TerminatedSafety Study of MGD009 in B7-H3-expressing TumorsThe purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors.NCT02628535·Los Angeles, California and 19 others

Active not recruitingStudy of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaThe purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.NCT06608927·Phoenix, Arizona and 110 others

CompletedStudy to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid TumorsThe primary objective of the study is to determine the maximum tolerated dose of andecaliximab monotherapy and to evaluate the safety and tolerability of andecaliximab (formerly…NCT01803282·Birmingham, Alabama and 17 others

CompletedFOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic CancerThis randomized phase II trial studies how well modified irinotecan hydrochloride, leucovorin calcium, fluorouracil (FOLFIRI) and veliparib as a second line of therapy work…NCT02890355·Mobile, Alabama and 782 others

CompletedCapecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic CancerRATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…NCT00983268·Nashville, Tennessee

CompletedAZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including LymphomasThis is a first-time-in-man (FTIM) multicenter, dose escalation study designed to investigate the safety, pharmacokinetics, and pharmacodynamics of AZD5153 in patients with…NCT03205176·Sarasota, Florida and 3 others

CompletedPhase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid TumorsThis is a Phase 1 open-label study of SN2310 Injectable Emulsion in patients with advanced solid malignancies.NCT00385177·Philadelphia, Pennsylvania and 1 other

RecruitingA Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H MutationPhase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.NCT06778863·Scottsdale, Arizona and 20 others

Not yet recruitingIKS04 Regimen in Advanced Solid Tumors That Express CA242This study will evaluate the safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of the IKS04 Regimen and identify a recommended phase…NCT07738939·Los Angeles, California and 3 others

CompletedA Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid TumorsThis was a phase I dose escalation trial designed to determine the maximum tolerated dose (MTD) for the combination of romidepsin (depsipeptide) and gemcitabine.NCT00379639·Nashville, Tennessee

TerminatedAn Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced MalignanciesThis is an open-label study of INCB047986 given to two distinct groups of patients (Group 1 and Group 2) with advanced malignancies.NCT01929941·Atlanta, Georgia and 2 others

CompletedA Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic CancerThe study consists of a Phase1b lead-in portion to determine the maximum tolerated dose (MTD) of OMP-59R5 in combination with nab-paclitaxel and gemcitabine followed by a Phase 2…NCT01647828·Goodyear, Arizona and 25 others

PreviousPage 4 of 15Next

Other Conditions in Nashville

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia